Master the CAMLPR Transfusion Test with interactive questions and detailed explanations. Boost your knowledge and ensure you're exam-ready with comprehensive study resources!

Multiple Choice

Which facility is typically consulted when complex antibodies against high-incidence antigens are suspected?

When antibodies against high-incidence antigens are suspected, a reference laboratory is needed because identifying these antibodies and finding compatible blood requires specialized expertise, extensive and rare antigen panels, and advanced testing techniques beyond what a typical hospital transfusion service routinely performs. A reference lab can perform confirmatory antibody identification, extended phenotyping or genotyping, adsorption/elution studies, and use specialized serologic methods to pinpoint the exact specificity. They also maintain access to rare antigen-negative donor panels and coordinate the production of antigen-negative units if possible, minimizing transfusion risk. Relying only on the local hospital transfusion service may leave gaps in resources or expertise for rare antibodies. Repeating testing at the same lab doesn’t address the fundamental need for broader panels and advanced methodologies. Autologous transfusion, while useful in certain contexts, does not resolve the issue of finding compatible blood when an alloantibody against a high-incidence antigen is present.

When antibodies against high-incidence antigens are suspected, a reference laboratory is needed because identifying these antibodies and finding compatible blood requires specialized expertise, extensive and rare antigen panels, and advanced testing techniques beyond what a typical hospital transfusion service routinely performs. A reference lab can perform confirmatory antibody identification, extended phenotyping or genotyping, adsorption/elution studies, and use specialized serologic methods to pinpoint the exact specificity. They also maintain access to rare antigen-negative donor panels and coordinate the production of antigen-negative units if possible, minimizing transfusion risk.

Relying only on the local hospital transfusion service may leave gaps in resources or expertise for rare antibodies. Repeating testing at the same lab doesn’t address the fundamental need for broader panels and advanced methodologies. Autologous transfusion, while useful in certain contexts, does not resolve the issue of finding compatible blood when an alloantibody against a high-incidence antigen is present.